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BACKGROUND: Few cohort studies have investigated Epstein–Barr virus (EBV) infection before the occurrence of gastric cancer.
METHODS: Among 14440 cohort participants, 100 incident gastric cancer cases were individually matched to two controls.
Epstein–Barr virus antibodies IgG and IgA against viral capsid antigen (VCA), EBV nuclear antigen (EBNA) antibody IgG, and early
antigen (EA) antibody IgG were measured using enzyme immunoassays (EIAs).
RESULTS: The highest titres of VCA IgG (odds ratio (OR): 1.37, 95% confidence interval (CI): 0.62–3.06) or EBNA IgG (OR: 0.87, 95%
CI: 0.51–1.46) were not associated with gastric cancer risk.
CONCLUSION: Higher levels of VCA IgG or EBNA IgG were not associated with increased risk of gastric adenocarcinoma in Koreans.
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Epstein–Barr virus was classified as a group I carcinogen for
Burkitt’s lymphoma, nasopharyngeal cancer, Hodgkin’s and non-
Hodgkin’s lymphoma (IARC, 1997), and the elevated levels of EBV
capsid antigen (VCA) and EBV early antigen (EA) were detected
before the development of Burkitt’s lymphoma (Geser et al, 1982),
nasopharyngeal cancer (Chien et al, 2001), Hodgkin’s and non-
Hodgkin’s lymphoma (Lehtinen et al, 1993), and testicular cancer
(Akre et al, 1999; Macsween and Crawford, 2003).
Epstein–Barr virus infection is believed to be related to 5–16%
of gastric adenocarcinomas, with variations across populations
(Burgess et al, 2002; Macsween and Crawford, 2003; Correa et al,
2004; Herrera-Goepfert et al, 2005). Most studies to date have been
tumour tissue-based, providing information about the role of EBV
in gastric carcinogenesis, but providing limited information on the
association between EBV infection and gastric cancer, particularly
adenocarcinoma – the most prominent histology (Tokunaga and
Land, 1998; Chang and Kim, 2005; Akiba et al, 2008). The few
epidemiological studies of EBV infection and gastric cancer, have
mainly been limited by small size and non-prospective design
(Levine et al, 1995; Shinkura et al, 2000). A recent case–control
study with 185 gastric cancers did not take account of the possible
contribution of Helicobacter pylori to the question (Koshiol et al,
2007).
We carried out a nested case–control study within the Korean
Multi-Center Cohort (KMCC) study of the possible relationship
between EBV-specific antibody titres and gastric cancer, adjusting
for H. pylori infection status.
MATERIALS AND METHODS
Individuals in this nested case–control study were participants in
the KMCC (Yoo et al, 2002; Gwack et al, 2006). Men and women
aged X30 years were recruited from 1993 to 2002. Informed
consent was obtained from all participants who were enrolled in
this study, and the Institutional Review Board of Seoul National
University Hospital approved the study protocol (Review No.
C-0603-161-170). Blood samples were collected after an overnight
fast, processed within 8h, stored at  201C for 2–3 days, and
transferred to a central site where they were preserved at  801C.
A total of 14440 men and women aged X30 years were recruited
from 1993 to 2002. Incident cancer cases were identified by a
computerised record linkage to the Korea Central Cancer Registry
database and the National Health Insurance database using
resident registration numbers. The last date of follow-up was 31
December 2002, and 100 incident gastric cancer cases were
identified among the 14440 cohort members by the end of the
follow-up period. Among participants who were alive and had no
period of follow-up loss at the date when each case was diagnosed,
controls were selected and matched 1:2 by incidence density
sampling for the year of enrolment, area of residence, age within
5 years, and gender. The follow-up period was defined as the date
of recruitment to the end of follow-up or to death. For the case
group, the end of the follow-up date was defined as the date of
diagnosis from the Korea Central Cancer Registry database.
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cially available enzyme-linked immunosorbent assays (ELISA),
namely EBV viral capsid antigen (VCA) IgG (EBV VCA IgG; Zeus
Scientific, Raritan, NJ, USA), EBV VCA IgA (EBV VCA IgA; IBL,
Hamburg, Germany), EBV nuclear antigen (EBNA) IgG (EBNA
IgG; Zeus Scientific), and EBV EA IgG (EBV EA IgG; IBL).
The laboratory was blinded to the case–control status. For
quality control of EBV VCA IgG and EBNA IgG, one negative
and one positive control was included in each plate of 96-wells.
Sensitivity for EBV VCA IgG was reported to be 98.3%
and specificity 98.1% compared with an immunofluorescence
assay. The sensitivity for EBNA IgG was reported to be 94.4%
(90.0–97.3%) and specificity 98.9% (93.8–100%) compared
with another ELISA system currently in commercial distribution.
Four kinds of control samples were used for quality control of EBV
VCA IgA and EA IgG, according to the manufacturer’s guidelines:
one negative control, one cutoff control, one weakly positive
control, and one positive control in each plate. The relative
sensitivity and specificity for EBV VCA IgA and EA IgG was
reported to be 495% compared with another ELISA method.
These ELISA methods from various companies have been shown to
correlate closely with immunofluorescence serology (Bruu et al,
2000).
Seropositivity for H. pylori antibody was identified by testing the
expression of H. pylori-specific antibody IgG using immunoblot
kits (Helico Blot 2.1; MP Biomedicals Asia Pacific, Singapore,
Singapore).
Antibody titres were categorised into binary variables as
negative or positive, including indeterminate as positive for
statistical analysis. The titres of VCA IgG and EBNA IgG were
re-categorised into three tertile groups based on titres of control
groups.
Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated using a multivariate conditional logistic regression
model. The SAS software version 9.1 (SAS Institute, Cary, NC,
USA) was used for all statistical analyses.
RESULTS
Table 1 shows the basic characteristics between cases and controls.
Adenocarcinoma comprised 87% of the gastric cancer cases, 2%
were other tumours, including single cases of malignant carcinoid
tumour and squamous cell carcinoma in situ; 11% were
unspecified.
Viral capsid antigen IgG, which develops early in EBV infection
and persists throughout life, was positive in 94% of the cases
and in 92% of the controls (P¼0.4). Epstein–Barr virus
nuclear antigen IgG, another antibody indicating latent infection,
was positive in 79% of the cases and in 82% of the controls
(P¼0.4). Viral capsid antigen IgA, an indicator of recent infection,
was positive in 2% of the cases and in 3% of the controls. Lytic
enzyme EA IgG was positive in 12% of the cases and in 11% of the
controls.
Crude and adjusted ORs for VCA IgG, VCA IgA, EBNA IgG, and
EA IgG of indeterminate and positive categories compared with the
negative category were not significantly associated with gastric
cancer risk (Table 2). This remained the case when VCA IgG and
EBNA IgG positive groups were re-categorised by the titre level of
below and above median, higher titre levels. When the analysis was
restricted to adenocarcinoma case pairs, the OR for the highest
tertile of VCA IgG was 1.33 (95% CI: 0.59–3.00) and that of EBNA
was 0.92 (95% CI 0.53–1.58) compared with the negative category
(Table 3). For gastric adenocarcinoma pairs, including those who
were diagnosed more than 2 years after enrolment, the ORs for
the highest category of VCA IgG and EBNA IgG vs the negatives
were 1.53 (95% CI: 0.62–3.75) and 1.23 (95% CI: 0.64–2.36),
respectively.
DISCUSSION
In this study, more than 80% of the study participants tested
positive for EBV latent infection antibodies (EBV VCA IgG and
EBNA IgG), and no significant association between seropositivity
for latent EBV infection and gastric cancer risk was observed.
Even after restricting the analysis to adenocarcinoma pairs
who were in follow-up more than 2 years after enrolment, there
was no significant association between antibody levels and gastric
cancer risk.
The highest category of VCA IgG and EBNA IgG titres had an
increased risk of gastric adenocarcinoma in a nested case–control
study of 54 cases and controls, but the difference was not
significant (Levine et al, 1995). A recent Chinese nested case–
control study suggested an opposite pattern, that a high VCA IgG
level might be associated with a lower risk of cardiac gastric
cancers (Koshiol et al, 2007). In our study, EBV latent infection
antibodies were not associated with gastric cancer risk. These
differences may be due to infection by different EBV strains,
which are believed to influence EBV-infected gastric cancer
worldwide in combination with different environmental factors
(Herrera-Goepfert et al, 2005).
Another possible reason for these inconsistencies may be an
interaction between H. pylori and EBV infection, which is poorly
understood. In this study, we measured seropositivity of H. pylori
Table 1 Baseline characteristics of the patients with gastric cancer and
controls
No. (%)
Variables Cases (n¼100) Controls (n¼200) P-value
Age at enrollment (years) 0.49
a
p59 31 (31.0) 49 (24.5)
60–69 46 (46.0) 100 (50.0)
X70 23 (23.0) 51 (25.5)
Male (%) 67 67 —
Cigarette smoking 0.32
a
Never 40 (40.0) 81 (40.5)
Past 14 (14.0) 32 (16.0)
Current 46 (46.0) 87 (43.5)
Alcohol consumption 0.42
a
Never 50 (50.0) 101 (50.5)
Past 12 (12.0) 15 (7.5)
Current 38 (38.0) 84 (42.0)
Education (years) 0.65
b
None 27 (27.0) 64 (32.0)
1–12 71 (71.0) 133 (66.5)
X13 2 (2.0) 3 (1.5)
H. pylori seropositivity (%) 89 (89.0) 181 (90.5) 0.68
a
Follow-up duration (years) —
o2.0 37 (37.0)
2.0–4.9 46 (46.0)
X5.0 17 (17.0)
Tumor sites —
Cardia 7 (7.0)
Non-cardia 75 (75.0)
Unspecified 18 (18.0)
Pathologic type —
Adenocarcinoma 87 (87.0)
Others 2 (2.0)
Unspecified 11 (11.0)
H. pylori¼Helicobacter pylori.
aw
2-test.
bFisher’s exact test.
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H. pylori and EBV VCA IgG and EBNA IgG were not statistically
significant (P¼0.87 and P¼0.79, respectively; data not shown).
However, an interaction between both infections might be
plausible, as both H. pylori and EBV infection have a role in
carcinogenesis in the pathway of inflammation, chronic infection,
and autoimmune pathway (Ouburg et al, 2005; Gwack et al,
2006). Several candidate gene approach studies suggest that EBNA
genes interact with inflammatory and tumour suppressor genes,
which has implications in gastric carcinogenesis (Ouburg et al,
2005).
In the analysis of EBNA, EA, and VCA antibodies, immuno-
fluorescence assay methods are more time consuming and difficult
to interpret, but are more specific, have high resolution, and stand
as the ‘gold standard’ technique. Enzyme immunoassay (EIA) is
often used in clinical laboratories because of its reliability in high-
throughput analysis (Gartner et al, 2003). The validity of the EIA
kits is supported by reasonably high sensitivity (95–100%) and
specificity (86–100%), compared with the indirect immunofluor-
escence assay as a gold standard (Bruu et al, 2000; Gartner et al,
2003). Large-scale population-based studies have recently used EIA
(Tedeschi et al, 2007).
In our study, pathological specimens were not collected so that
the association between EBV antibody titre and gastric cancer was
not compared among EBV-related and non-EBV-related gastric
cancer cases. We cannot exclude chance effects due to our small
numbers, and further studies are required. Antibodies were
checked only at the time of enrolment and not re-tested, which
omitted detailed information about EBV infection status during
follow-up.
Table 2 Odds ratios of gastric cancer risk according to the Epstein–Barr virus (EBV) antibody titres
Antibody Category Cases (n¼100) no. Controls (n¼200) no. (%) cOR (95% CI) aOR (95% CI)
a
VCA IgG Negative 3 11 (5.5) 1.00 — 1.00 —
Indeterminate or positive 97 189 (94.5) 1.26 (0.60–2.62) 1.24 (0.59–2.62)
VCA IgA Negative 98 194 (97.0) 1.00 — 1.00 —
Indeterminate or positive 2 6 (3.0) 0.87 (0.35–2.15) 0.83 (0.33–2.09)
EBNA IgG Negative 19 31 (15.5) 1.00 — 1.00 —
Indeterminate or positive 81 169 (84.5) 0.88 (0.56–1.39) 0.85 (0.54–1.36)
EA IgG Negative 88 178 (89.0) 1.00 — 1.00 —
Indeterminate or positive 12 22 (11.0) 1.04 (0.65–1.65) 1.07 (0.67–1.72)
VCA IgG Negative 3 11 (5.5) 1.00 — 1.00 —
Seropositive, below median 51 94 (47.0) 1.28 (0.61–2.71) 1.27 (0.60–2.72)
Seropositive, above median 46 95 (47.5) 1.23 (0.58–2.61) 1.21 (0.56–2.60)
EBNA IgG Negative 19 31 (15.5) 1.00 — 1.00 —
Seropositive, below median 36 84 (42.0) 0.86 (0.53–1.38) 0.81 (0.50–1.32)
Seropositive, above median 45 85 (42.5) 0.92 (0.56–1.50) 0.90 (0.55–1.49)
VCA IgG Negative 3 11 (5.5) 1.00 — 1.00 —
1T (lowest) 36 65 (32.5) 1.28 (0.60–2.70) 1.27 (0.59–2.72)
2T 24 64 (32.0) 1.10 (0.50–2.41) 1.09 (0.49–2.42)
3T (highest) 37 60 (30.0) 1.37 (0.63–3.00) 1.37 (0.62–3.06)
EBNA IgG Negative 19 31 (15.5) 1.00 — 1.00 —
1T (lowest) 22 57 (28.5) 0.83 (0.50–1.37) 0.78 (0.46–1.30)
2T 31 56 (28.0) 0.94 (0.56–1.56) 0.93 (0.55–1.57)
3T (highest) 28 56 (28.0) 0.90 (0.54–1.50) 0.87 (0.51–1.46)
aOR¼adjusted odds ratio; CI¼confidence interval; cOR¼crude odds ratio; EA¼early antigen; EBNA¼EBV nuclear antigen; IgA¼immunoglobulin A; IgG¼immunoglobulin
G;; VCA¼viral capsid antigen.
aConditional logistic regression model adjusting for age (continuous), education (none, 1–12 years, more than 13 years), alcohol consumption
(never, past, current), cigarette smoking (never, past, current), and H. pylori antibody seropositivity (yes or no).
Table 3 Odds ratios of gastric adenocarcinoma risk according to the Epstein–Barr virus (EBV) antibody titres
Gastric adenocarcinoma (cases¼87, controls¼174) Diagnosed X2 years of enrolment (cases¼63, controls¼126)
Antibody No. cases/controls aOR (95% CI)
a No. cases/controls aOR (95% CI)
a
VCA IgG
Negative 3/11 1.00 – 3/10 1.00 –
1T (lowest) 30/55 1.26 (0.59–2.71) 19/41 1.10 (0.48–2.49)
2T 21/52 1.15 (0.51–2.60) 15/38 1.07 (0.45–2.57)
3T (highest) 33/56 1.33 (0.59–3.00) 26/37 1.53 (0.62–3.75)
EBNA IgG
Negative 15/29 1.00 – 11/24 1.00 –
1T (lowest) 20/48 0.87 (0.51–1.48) 14/41 0.91 (0.49–1.68)
2T 29/45 1.11 (0.64–1.92) 21/29 1.37 (0.71–2.67)
3T (highest) 23/52 0.92 (0.53–1.58) 17/32 1.23 (0.64–2.36)
aOR¼adjusted odds ratio; CI¼confidence interval; EBNA¼EBV nuclear antigen; IgG, immunoglobulin G; VCA¼viral capsid antigen.
aConditional logistic regression model
adjusting for age (continuous), education (none, 1–12 years, more than 13 years), alcohol consumption (never, past, current), cigarette smoking (never, past, current), and
H. pylori antibody seropositivity (yes or no).
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cohort study, and sera were collected before the diagnosis of
gastric cancer, which may minimise any possibility of misclassi-
fication for exposure. We restricted our analysis to gastric
adenocarcinoma cases. If lymphoepithelioma-like cancer was
included among the ‘unspecified’ pathological group, the OR
may have tended towards null. To exclude potentially developing
cases before or near the period of enrolment, we restricted our
analysis to individuals who were diagnosed after 2 years of
enrolment.
In summary, our results provide little support for the hypothesis
that increased levels of EBV antibodies are related to gastric
adenocarcinoma.
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